Biotechnology stocks slide as the resignation of brands considered negative for the sector

The actions of several biotechnological and biopharmatic names are under pressure on Monday after the resignation of the head of the Evaluation and Research Center on the Evaluation and Research of Food and Drug Administration of Food and Drug Administration, Peter Marks. RBC Capital claims that development is “not good for the biotechnological industry even beyond vaccines”. Expressing a similar opinion, BMO Capital told investors this morning that he considered the news as a “significant negative” for the biopharmacy and biotechnological sectors.

“Not good” for the biotechnological sector: RBC Capital believes that the resignation of the head of the Center for Biologics Evaluation and Research of the FDA, Peter Marks, is “not good for the biotechnology industry, even beyond vaccines”. The marks had been an ardent defender of the approval processes more flexible and effective for drugs, in particular those for orphan diseases such as gene therapies, said the firm in investors in a research note.

In addition, the news highlights the risk of additional attrition between the leaders and the FDA staff, potentially frustrated by the “lack of expertise / experience of Robert F. Kennedy Jr. The company expects a certain weakness for biotechnology stocks” while uncertainty continues to be perpetuated “. RBC believes that the companies of its coverage which could see the biggest impact include Sarepta (SPRT), Legend Biotech (Lign), Gilead (Gild), Regeneron (Regn), Vertex Pharmaceuticals (VRTX), PTC Therapeutics (PTCT), Galapagos (GLPG), RGNXBIO (RGX) Avidity Bioscices (RNA), Dynne), RGNX), Avidity BioScices (RNA), Dynne), RGNX), Avidity BioCice (RNA), Dynne), RGNX), Avidity Bioscice (RNA), Dynne) La Therapeutics (DYN), Moderna (Arnm), Karyopharm (Kpti) Meiragtx (MGTX) and Pacira (PCRX).

Negative “significant”: BMO Capital analysts consider that the departure of Peter marks the FDA as a “significant negative” for the biopharmacy and biotechnological sectors. The independence of the FDA is “rooted in good scientific rigor is essential for their effective functioning”, the firm tells investors in a research note. BMO says that even if she is positive about Marty Makary’s confirmation as a commissioner of the FDA, “anti-science, the politicization of the FDA goes against the agency’s mission”. The company believes that the resignation of notes “does nothing to reassure investors or provide relief”. BMO provides that several publishing and therapy genes will be under pressure after the resignation of brands, namely Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Precision Biosciences (DTIL), 4D Molecular (FDMT), Metagénomi (MGX), Neurogen (NGNE), Intellia Therapeutics (NTLA), Prime Medicine (PRME), Rocket Pharmaceuticals (RCKT) Therapies (Tsha), and Verve), Taysha Genere Therapies (Tsha), and Verve), Taysha Genehe Therapies (The), and Verve), Taysha Genehe Therapies (The), and Verve), Taysha Genehe Therapies (TheL Therapeutic (Verv).